Method of producing protein reducing content of cholesterol in blood of mammals

专利摘要:
A hypocholesterolemically active protein capable of reducing the blood cholesterol in mammals having the following characteristics: (a) Molecular weight by gel filtration: 30,000 ± 7,000 (b) Isoelectric point: 7.9 ± 0.2 (c) Amino acid composition (mole %): (d) Pattern of electrophoresis: a sharp band on the anode side on polyacrylamide gel electrophoresis. This hypocholesterolemically active protein is derived from a microorganism belonging to the genus Streptococcus.
公开号:SU1423002A3
申请号:SU833682599
申请日:1983-12-27
公开日:1988-09-07
发明作者:Каваи Ясуо；Язава Куцунага
申请人:Кабусики Кайся Эдванс Каихацу Кенкюдзе (Фирма)；
IPC主号:

专利说明:


SP
This invention relates to biotechnology and relates to the preparation of a hypocholesterinemic active protein (CRP.
To implement the method, one of seven strains isolated from the feces of a healthy person is used. Registered at the Fermentation Research Institute (FR1) and deposited with the following FERM-BP numbers: Streptococcus faecium ADV 1009 PERM BP-296, Streptococcus faecalis ADV 9001 BP-297, Streptococcus avium ADV 2003 FERM BP-298, Streptococcus salital ADV 10001 FERM BP-299, Streptococcus durans ADV 3001 FERM BP-ZOO, Streptococcus mitis ADV 7001 FERM BP-301, Streptococcus eguinus ADV 8001 FERM BP-302.
Cultural, morphological, physiological and biochemical properties of the strains are presented in Table 1,
The method is carried out as follows.
The cultivation of one of these microorganisms is carried out by a known method. For example, biomass can be obtained by stationary cultivation in nutrient broth under anaerobic conditions and can be harvested by centrifuging a bacterial culture.
The composition of the nutrient broth, g;
Trypticase 10
Yeast
extract 5
Tryptosis 3
Konro 3
 3
Triammonium citrate 2
Twin 80 1
Glucose 20
Hydrochloride
cysteine 0,2
Saline
5 MP solution
Distilliro
bath water Up to 1 l
RP 7, sterilized with heating for 15 minutes.
Saline contains, g g
MgSO-7HjO11.5.
ReB04-71TSO0,68
Mn04-2H, 02.4
Distilled water 10 MP
Preparation of CRP protein.
- Q 5
0 5
ABOUT
0
five
0
five
five
Isolation of microorganisms. Each of these microbial strains is inoculated into Rogosa nutrient broth, incubated without stirring at 37 ° C for 5-10 hours under aerobic conditions, feeding the nutrient broth with a certain concentration of the 1st viable bacterial cells. This nutrient broth is continuously centrifuged at a speed of 12000 rpm. The collected bacterial cells are then washed in saline (0.85% NaCl) up to three times.
Bacterial cell disintegration. The washed cells are suspended in physiological saline solution and thermally treated at 115 ° C for 10 minutes. Washed and suspended in physiological saline bacterial cells disintegrate with ultrasound.
Remove fat from cells. Disintegrated cell suspension is mixed with the mixture, chloroform - methanol (2: 1 v / v). The components extracted with the organic solvent are then completely removed by centrifuging at a spin speed of 3000 rpm for 10 minutes and the chloroform layer is removed.
Processing with proteolytic enzymes (lysis). Fat-free cells are treated with proteolytic enzymes, such as pronase, trypsin and pepsin. Of these proteolytic enzymes, pronaz is the most suitable for this purpose.
Cleaning up Precipitating agents, such as trichloroacetic acid (TCA) or ammonium sulfate, are introduced into the surface layer of the centrifugation of the proteolytic reaction mixture to precipitate the protein fraction. The protein fraction is then treated with an appropriate nuclease to remove nucleic acid components, such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in this fraction. After this enzyme treatment, re-dialysis is performed.
The partially purified protein fraction is subjected to gel filtration and fractionation with ammonium sulfate, and finally a pure protein preparation, CRP protein, is obtained.
Physico-chemical characteristics of CRP protein.
Chemical nature and solubility characteristics: white powder,
very soluble in water, as well as soluble in acetone. When mixing the CRP protein solution. with ammonium sulfate or TCA in the cold (4 ° C), respectively, turbidity is observed and

fall sediment.
The molecular weight of the CRP protein is 30,000 ± 7,000, as determined by gel filtration using a Toyopearl HW55 column and 25 mmol of Tris-HCl buffer solution containing 0.3 mol NaCl (pH 7.5).
The isoelectric point of the CRP protein was measured by the method of iso-electric focusing using 5% Physiological characteristics. CRP protein has the ability to lower cholesterol in the blood of mammals when administered through the mouth. Such activity is within the range of pH from 4.1 to 10.9.
20
go polyacrylamide gel containing ampholin (pH 3.5-10), with a final concentration of 2% at 4 ° C, at a stable voltage of 200 V for
, 3 h. For the electrolysis solution of the cathode 25 during storage of CRP protein. and anode using solutions of 0.02 mol. Pharmacological activities of the protein-resistant at -80 to + 115 ° С and
2.60 2.51 1.56 1.30 0.16
Cysteine
Disc electrophoresis curves, Electrophoretic analysis of CRP protein (25 µg) using a disc was performed using a polyacrylamide gel (7% polyacrylamide) in a buffer solution (Tris-glycine, pH 8.3) at 4 mA / gel for 2 , 5 h. A curve characteristic of a protein with a sharp maximum of the specimen obtained is obtained at a distance of 4.2 iO, 2 cm from the anode.
Physiological characteristics. CRP protein has the ability to lower cholesterol in the blood of mammals when administered through the mouth. Such activity is within the range of pH from 4.1 to 10.9.
when storing CRP protein. Pharmacological activity of the beloustable in –80 to + 115 ° С and
HjPO-} and 1 mol of NaCl, respectively. A sample of 100 µg is used, the staining is carried out by means of the Coomassie Brilliant Blue-250 dye. The isoelectric point is 7.9tO, 2.
The composition of amino acids. A sample (1 mg) is suspended in 1 ml of hydrochloric acid and injected into an ampoule, frozen in a mixture of dry ice-methanol, and air is displaced with gaseous nitrogen (N) in a vacuum. Such gas displacement is repeated three times, the ampoule is sealed in vacuum. After hydrolysis for 24 hours in the heating system, the hydrochloride is removed by evaporation in a rotary evaporator under vacuum, and the sample is dissolved in 200 µl 1/50 HCl. Then, 50 μl of this sample is analyzed in an amino acid analyzer.
Amino acid composition, mol.%:
n
n
25.23 10.98 10.34 8.20 6.39 5, 5.41 5.18 4.23 4.1.9 3.46 2.62
ka CRP.
Pharmacological effects. And a atherosclerotic drug, which consists of CRP protein, can cause an extremely strong decrease in blood cholesterol in mammals. Therefore, this medicine is used as a therapeutic or prophylactic agent for diseases directly related to atherosclerosis, hyperlipidemia, hyperlipoproteinemia, xanthomatosis, cholelithiasis, hypertension, diabetes and other diseases.
0
five
0
five
lez mi.
The preparation according to the invention can be used for mammalian animals, it is administered via yt, intraperitoneal or intravenous injection, and other means. . The dose of a single dose of the drug is approximately 1 µg - 1 g per 1 kg of patient weight. It is preferable to introduce through the mouth about 0.1-1.00 mg per 1 kg of weight. Any form of the drug can be selected: c, as a solution in physiological saline solution and in another solvent, as an injectable preparation, as a powder prepared by lyophilization and in other ways, as candles, gastric coated tablets, sublimate tablets It is held at 4 ° C for 3 hours with stirring and centrifuged at a rotation speed of 3000 g / min for 10 minutes to obtain a precipitated and floated fraction. The same volume of TCA is introduced into the precipitated fraction, and this procedure is repeated. The resulting precipitated 10 product was washed three times with ethyl ether to remove the TCA, dissolved in 50 MP of distilled water, neutralized with GI, NaOH, dialyzed to completely remove TCA and, then prepared and cleaned 15 centrifuge. Get 345 mg
zeros, capsules, etc., together with their respective carriers (for example, collapse of malar, dextrin), diluent residues (for example, calcium carbonate, lactose), diluents (for example, physiological saline , distilled water) and t, d.
Acute toxicity. CRP protein is more than 802 mg / kg by intraperitoneal injection into mice. This protein is generally non-toxic when administered through
Roto,
Example sa protein CRP,
Bacteria of Streptococcus faecium ADV 1009 (FERM BP-296) are accumulated in 2 liters of Rogosa nutrient broth with a final concentration of 1 ml of bacterial cells. Inoculated nutrient medium is incubated at 37 ° C for 10 hours without trampling under aerobic conditions. x, resulting in 10 bacterial cells per 1 ml of culture medium. Bacterial cells are harvested by continuous centrifugation at a centrifuge speed of 12,000 rpm, rinsed with physiological saline (NaCl) and suspended in the same solution, obtaining 100 ml of cell suspension of dry weight) precipitated fraction.
In the resulting precipitated fraction (345 mg), 5 ml (0.1 mol) of trisacetate buffer (pH 8.0), 1 mp 20 (0.1 mol) of magnesium acetate and 0.06 ml of deoxyribonuclease (2 g / ml deoxy - ribonucleases I) and incubated at 37 ° C for 1 hour. Then the reaction mixture is dialyzed using
25 distilled water as a solvent for the cellulose tube for three days, and the dialysis substances have a molecular weight less than 3500. The fraction is boosted to dry. The resulting product is then suspended in 5 IL (0.05 mol) acetate buffer (pH 4.6) containing 440 mol. ribonuclease Tj, incubated for 3 h and dil. The dialyzed fraction is denoted as purified fraction I (molecular weight 7 20000, dry weight
centerpiece 2 10 VMn,
Suspension of bacterial cells under-. a.pizyut using distilled heat treatment with water as the solvent, 115 ° C for 10 min, and three-fold it with a chloro mixture (2: 1 vol / v) to remove the fat.
Fat-free bacterial suspension Q mass 285 mg).
The centrifugation is rotated. The purified fraction I is again processed with a centrifuge of 3000 rpm for 10 minutes with ribonuclease T and dialyzed, and the bottom layer, for example, is cooled, to obtain the purified fraction II rome Y5. The aqueous layer is used (weight per dry weight is 274 mg), Fraction is used as a starting material -. II is fed to the chromatographic
Toyopearl HW55 column, which uses 25 mmol Tris-HCl buffer (pH 7.5) p containing 0.3 mol NaCl.
La for the subsequent purification steps, the Source material is treated with 20 mg of pronase (protease type XIV). in 100 ml of phosphate buffer (pH 7.8) containing - O ,, 0015 mol of CaCli at 47 s for 24 hours, and the subsequent processing of 10 mg of penetration is carried out under the same conditions
The product treated with leprosy is divided into centrifugal fractions with a centrifugal rotation speed of 3000 rpm E for 10 units. 1/9 of the volume of 100% (May „vol.) TCA is added to the surface fraction,
Sleep dry weight) precipitated fraction.
In the resulting precipitated fraction (345 mg), 5 ml (0.1 mol) of trisacetate buffer (pH 8.0), 1 mp (0.1 mol) of magnesium acetate and 0.06 ml of deoxyribonuclease (2 g / ml deoxy- ribonuclease i) and incubated at 37 ° C for 1 hour. Then the reaction mixture is dialyzed using
ABOUT
distilled water as the solvent of the cellulose tube for three days, and the disintegrating substances have a molecular weight less than 3500. The dialyzed fraction is evaporated to dryness. The resulting product is then suspended in 5 IL (0.05 mol) acetate buffer (pH 4.6) containing 440 mol. ribonuclease Tj, incubated for 3 h and dil. The dialyzed fraction is denoted as purified fraction I (molecular weight 7 20000, dry weight
a.pizyrut using distilled water as a solvent.
Purified fraction I is again treated with ribonuclease T and dialyzed to obtain purified fraction II (dry weight of 274 mg), Fraction II is fed to the chromatographic
Toyopearl HW55 column, which uses 25 mmol Tris-HCl buffer (pH 7.5) p containing 0.3 mol NaCl.
A portion eluted after 67 ml of the elution volume is treated with ammonium sulfate (saturation 55%), and the purified fraction III (dry weight 205.5 mg) is obtained from the surface layer of the ammonium sulfate fractionate product.
Since fraction III contains trace amounts of sugar, it is treated three times with 10% TCA and dialyzed under the same conditions.
Purified CRP protein is obtained (dry mass 197.3 g).
In tab. 2 shows the yield and amount of protein according to the method of Lowry, RNA-microbial method, DNA method using diphenylamine and Sugars using phenol HjSO in the cell process. Given in Table. .2 values are dry mass.
The specific activity shown in Table. 2 shows the ability of each fraction to lower cholesterol in normal rats per unit weight of rat.
15 liquid nutrient medium containing sources of carbon, nitrogen and mineral salts, followed by separation of the resulting biomass, lysis of its sequentially thermal and enzyme. The CRP protein can be extracted and purified using other specified bacterial strains.
The use of the invention allows one to work with the treatment, separating to obtain a protein that has the method of sediment, processing it with ribonuclei to reduce cholesterolase content and purifying the target product dyne in the blood of mammals. alizom
I
Table 1
Cell shape Gram stain Hemolysis
Growth at a temperature, ° С:
ten
45. 50
Thermal stability at 60 ° C for 30 minutes
Growth in culture medium at pH 9.6
Weakening ability of methylene blue
with/
+ + +
Gelatin dilution

权利要求:
Claims (1)
[1]
Invention Formula
A method for producing a cholesterol-lowering protein in mammals, comprising: a strain of Streptococcus faecum PERM BP-296, Streptococcus faeca-, lis FERM BP-297, Streptococcus aviurn FERM BP-298, Streptococcus sali- valius FERM -299, Streptococcus durans FERM BP-300, Streptococcus mitis FERM BP-301 or Streptococcus eguinus FERM BP-302 are cultivated in
liquid nutrient medium containing sources of carbon, nitrogen and mineral salts, followed by separation of the resulting biomass, lysis of it sequentially with thermal and enzyme spheroid
 about(
+ - + +
el.
+ +
K23002
Ro: st in nutrient medium containing:
NaCl (6.5%) bile (40%)
Ammonia productivity
Hi | trolysis of hippuric acid
A nutritional medium containing
Note, x., - 2,3,5-triphenyltetraeolium chloride. x - not given
(ND).
ten
Continued table. one
+
+
N0
345 265.9 43.6 6.3 14.3 9.1
285 260,111,31,212,111,1
274 258,33,60,811,211,8
205.5 202.6 FootprintsFoot2.916.9
197.3 197.3- - - Footprints17.6
table 2

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1423002A3|1988-09-07|Method of producing protein reducing content of cholesterol in blood of mammals

---

EP0240348B1|1993-10-27|Agent for the removal of nucleic acids and/or endotoxin and method for the removal thereof

---

SU1732815A3|1992-05-07|Method for preparation of hypotriglyceridemic polysaccharides

---

FR2567540A1|1986-01-17|PROCESS FOR PREPARING A HUMAN LEUKOCYTE INTERFERON ALPHA-2

---

US3875007A|1975-04-01|Lipid metabolism improving and anti-atheromatic agent

---

KR20020071390A|2002-09-12|Manufacture method of hyluronic acid utilizing a microbe

---

CA1122526A|1982-04-27|Biologically active substance, preparation processand drugs containing same

---

US4824945A|1989-04-25|Hypocholesterolemically active RNA fractions

---

US3708576A|1973-01-02|Novel anti-inflammatory substances and production thereof

---

CN1511952A|2004-07-14|Recombined glucokinase

---

FI93969B|1995-03-15|Process for producing kedarcidin antibiotics

---

SU1724689A1|1992-04-07|Method for preparation of restriction endonuclease, recognizing and splitting the nucleotide sequence 5ъtgatca3ъ

---

US4833129A|1989-05-23|Hypocholesterolemically and/or hypotriglyceridemically active RNA fractions

---

CA1211392A|1986-09-16|Preparation of an antibiotic selectively effectiveagainst staphylococcus infections

---

SU787463A1|1980-12-15|Method of preparing thrombolytic enzyme

---

JP3629290B2|2005-03-16|Manufacturing method of substance

---

US3959467A|1976-05-25|Lipid metabolism improving and anti-atheromatic agent

---

KR830002535B1|1983-11-12|Process for preparing new biologically active substance

---

JPH0631280B2|1994-04-27|WS7739 substance and its manufacturing method

---

JP2548553B2|1996-10-30|Method for producing glutaminase

---

CN1284566A|2001-02-21|Preparation process of Lidamycin as one antineoplastic antibiotics

---

KR820000372B1|1982-03-25|Process for preparing biological active compound

---

FI59815C|1981-10-12|FREQUENCY REFRIGERATION FOR ALPHA-AMYLES INHIBITORS WITH STRUCTURAL STRUCTURES

---

KR910004362B1|1991-06-26|Novel superoxide dismutase

---

JP2578486B2|1997-02-05|New substance KS-502

同族专利:

---

公开号 | 公开日

---

ES8506806A1|1985-08-01|

---

DD215580A5|1984-11-14|

---

JPH0142280B2|1989-09-11|

---

ES528497A0|1985-08-01|

---

JPS59122428A|1984-07-14|

---

CA1225957A|1987-08-25|

---

EP0115157A3|1985-08-07|

---

AU2224283A|1984-07-05|

---

EP0115157A2|1984-08-08|

---

DE3377654D1|1988-09-15|

---

PL245380A1|1984-10-22|

---

US4812441A|1989-03-14|

---

PL140807B1|1987-05-30|

---

EP0115157B1|1988-08-10|

---

MX7656E|1990-06-11|

---

AU568521B2|1988-01-07|

---

HU191746B|1987-04-28|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO1997045530A1|1996-05-27|1997-12-04|UZILOVA, Irina Semenovna, Heiress of UZILOV|Use of streptococcus faecium strains and composition containing the same|GB930107A|1960-01-11|1963-07-03|Giuseppe Carlo Sigurta|Therapeutic oral preparation of micro-organisms|

---

FR3626M|1963-11-13|1900-01-01|Lucien Nouvel|Medicine for intestinal complaints.|

---

DE2106154C3|1971-02-10|1974-10-31|Morishita Pharmaceutical Co. Ltd., Osaka |Process for the production of a lactic acid bacteria preparation|

---

FR2405301B1|1977-10-04|1980-08-01|Api Labor|

---

ZA794413B|1978-09-01|1980-08-27|Us Government|Protection against dental caries|

---

US4268434A|1979-01-09|1981-05-19|Higerd Thomas B|Immunosuppressive extracellular product from oral bacteria|

---

JPS5946491B2|1979-03-14|1984-11-13|Kyokuto Shibosan Kk|

---

JPS5946492B2|1979-07-12|1984-11-13|Kyokuto Shibosan Kk|

---

JPS5943929B2|1979-08-13|1984-10-25|Satsuhoro Biiru Kk|

---

GB2077101B|1980-05-12|1984-08-08|Kyokuto Fatty Acid Corp|Antiallergic composition containing streptococci|

---

JPS57131723A|1981-02-10|1982-08-14|Yakult Honsha Co Ltd|Enzymatic activity inhibiting agent|

---

JPS58131917A|1982-02-01|1983-08-06|Advance Res & Dev Co Ltd|Agent for counteracting arteriosclerosis|

---

DE3305047A1|1982-02-19|1983-09-22|Terumo Kabushiki Kaisha trading as Terumo Corp., Tokyo|POLYSACCHARIDES, THEIR PRODUCTION AND THE THERAPEUTIC COMPOSITIONS CONTAINING THEM|

---

JPH0526768B2|1982-08-06|1993-04-19|Advance Kk|

---

JPH0142280B2|1982-12-28|1989-09-11|Advance Kk|

---

JPH0365362B2|1983-07-27|1991-10-11|

---

JP5612318B2|2010-01-21|2014-10-22|株式会社ニコン|Lens barrel and imaging device|US5932250A|1982-06-03|1999-08-03|Dcv, Inc.|Anti-cholesterolemic egg, vaccine and method for production, and use|

---

US5753268A|1982-06-03|1998-05-19|Dcv Biologics, L.P.|Anti-cholesterolemic egg, vaccine and method for production, and use|

---

JPH0526768B2|1982-08-06|1993-04-19|Advance Kk|

---

JPH0142280B2|1982-12-28|1989-09-11|Advance Kk|

---

JPH0566370B2|1984-12-24|1993-09-21|Advance Kk|

---

JPS625991A|1985-07-03|1987-01-12|Advance Res & Dev Co Ltd|Rna fraction having cholesterol or triglyceride lowering activity|

---

US5248688A|1986-09-10|1993-09-28|Dudrick Medical Research Fund I, Ltd.|Method and substrate composition for treating atherosclerosis|

---

US4945157A|1988-05-27|1990-07-31|University Of Florida|Novel Extraction procedure for protein G|

---

US5006472A|1988-06-03|1991-04-09|Miles Inc.|Enzymatic purification process|

---

US5449679A|1994-07-29|1995-09-12|Leonard; Robert J.|Process and products for reducing biological fluid levels of a lipid soluble waste|

---

US5674488A|1994-10-07|1997-10-07|Reich; John J.|Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol|

---

CN1111512C|1999-12-03|2003-06-18|华南农业大学|The dehydration of flocculate precipitate from waste water of monosodium glutamate and manufacturing feedstuff protein method|

---

EP1176208A1|2000-07-28|2002-01-30|Société des Produits Nestlé S.A.|Koji molds and use thereof for preparing cholesterol-lowering products|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

JP57227395A|JPH0142280B2|1982-12-28|1982-12-28|

---